Reardon Andrew bought LGND
August 3, 2026 · Form 4 insider transaction
Reardon Andrew bought 5,000 shares of Ligand Pharmaceuticals Incorporated at $52.27 per share, a transaction worth $261.4K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Acquired (buy-side)
Shares
5,000
Price
$52.27
Total value
$261.4K
InsiderReardon Andrew
Role—
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateAugust 3, 2026
Filing dateAugust 4, 2026
Shares owned after46,514
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1.